Breast Cancer Clinical Trial

Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance

Summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from malignant fluids such as pleural effusions and ascites.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient is ≥18 years of age
Written Informed Consent provided by patient
Diagnosis of any kind of carcinoma
Malignant fluid (e.g. pleural effusion or ascites) drainage is clinically indicated as part of SOC
Proceeding onto therapy for treatment
Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion Criteria:

Lack of informed consent
Unable to obtain sufficient sample

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT05461430

Recruitment Status:

Recruiting

Sponsor:

Travera Inc

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

xCures
Oakland California, 94612, United States More Info
Sarah Ginn, MD
Contact
707-641-4475
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT05461430

Recruitment Status:

Recruiting

Sponsor:


Travera Inc

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.